ArticleJournal of gastrointestinal cancer2019

Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.

Arthur C Houts et al.PubMed ↗Publisher ↗

No numbers read from the abstract.